Skip to content

Omeros OMER Interest coverage

Interest coverage at other companies

Arcus Biosciences logo
Arcus BiosciencesRCUS
-39.8×-15.5×
Allogene Therapeutics logo
Allogene TherapeuticsALLO
-155.3×-69.4×
Vera Therapeutics logo
Vera TherapeuticsVERA
-50.7×+1,690×
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
-4×-1.6×
Opko Health logo
Opko HealthOPK
-1×-0.4×

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$775.86M+313%
P/S8.6×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%
FCF margin-121.6%

Returns & leverage

See full
Return on equity86.6%
Debt / equity0.3×-1.1×
Current ratio+1.9×

Where this comes from

Calculated from Omeros’s reported figures.

Based on trailing twelve months.

The official record: Omeros’s 10-Q, filed August 9, 2023, on SEC EDGAR. View the filing →

Ask your AI about Omeros's interest coverage.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omeros's interest coverage?
Omeros (OMER) reported interest coverage of -5.8× in Q2 2023.
How has Omeros's interest coverage changed year-over-year?
Omeros's interest coverage increased by 25.8% year-over-year, from -7.9× to -5.8×.
What is the long-term trend for Omeros's interest coverage?
Over 2 years (2020 to 2022), Omeros's interest coverage has grown at a 31.9% compound annual growth rate (CAGR), from -4.1× to -7.2×.
What does interest coverage mean?
Trailing-twelve-month operating income (EBIT) divided by interest expense. Measures how many times over the company can cover its interest payments from operating profit.